ERBB2 and endometrial cancer: Although endometrial hyperplasia itself is not mediated by HER2-associated pathways, accumulating evidence demonstrates that HER2 amplification and overexpression play an important prognostic and therapeutic role in aggressive endometrial cancer subtypes.